PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 :
C07D 401/04, A61K 31/505 // (C07D 401/04, 239:00, 213:00)

A1

(11) International Publication Number: WO 99/03854

(43) International Publication Date: 28 January 1999 (28.01.99)

(21) International Application Number: PCT/EP98/04427

(22) International Filing Date: 16 July 1998 (16.07.98)

(30) Priority Data:
1764/97 18 July 1997 (18.07.97) CH

(71) Applicant *(for all designated States except AT US)*: NOVARTIS AG [CH/CH]; Schwarzwaldallee 215, CH–4058 Basel (CH).

(71) Applicant *(for AT only)*: NOVARTIS–ERFINDUNGEN VERWALTUNGSGESELLSCHAFT MBH [AT/AT]; Brunner Strasse 59, A–1235 Vienna (AT).


(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: ZIMMERMANN, Jürg [CH/CH]; Ahornweg 622, CH–4323 Wallbach (CH). SUTTER, Bertrand [FR/FR]; 6, rue des Pins, F–68220 Hésingue (FR). BÜRGER, Hans, Michael [DE/CH]; Maiengasse 28, CH–4123 Allschwil (CH).

(74) Agent: BECKER, Konrad; Novartis AG, Patent– und Markenabteilung, Lichtstrasse 35, CH–4002 Basel (CH).

(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published
With international search report.
Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(54) Title: CRYSTAL MODIFICATION OF A N–PHENYL–2–PYRIMIDINEAMINE DERIVATIVE, PROCESSES FOR ITS MANUFACTURE AND ITS USE



(I)

(57) Abstract

The invention relates to a new crystalline form of the methanesulfonic acid addition salt of 4–(4–methylpiperazin–1–ylmethyl)–N–[4–methyl–3–(4–pyridin–3–yl)pyrimidin–2–ylamino)phenyl]–benzamide of formula (I), which may be used for example for tumour therapy.